37.3
[]. Boĭko SS, et al. Mezhvidovye razlichiia farmakokinetiki kemantana [Interspecific differences in kemantan pharmacokinetics]. Eksp Klin Farmakol. 994;57(6):48-5.
[]. I E Kovalev, et al. Effect of adamantanone derivative possessing anti-HIV properties on the redox processes in the cytochrome P-45 system. Dokl Biochem Biophys. May-Jun:378:-3.
[3]. N V Kossii, et al. [Treatment of immunodeficient conditions caused by viral infection with the Soviet immunomodulator kemantan in patients with pulmonary tuberculosis]. Probl Tuberk. 99:(6):3-6.
[4]. S S Bo?ko, et al. [Interspecific differences in kemantan pharmacokinetics]. Eksp Klin Farmakol. 994 Nov-Dec;57(6):48-5.
[5]. S S Bo?ko, et al. [Kemantane pharmacokinetics in rats]. Biull Eksp Biol Med. 99 Nov;():5-3.
H3-H35-H39-H335
P6-P64-P7-P7-P8-P3+P35-P34+P34-P35+P35+P338-P33-P36+P364-P43+P33-P45-P5
GHS7